MUMBAI (NewsRise) -- As sales in key export markets dwindle, India's top drugmakers are under pressure to transform their product portfolio, a process that is proving painful for the companies as well as for investors.
Not only are profits from the mainstay generics business crumbling, the heavy capital investment required to make specialty drugs, including biologics and biosimilars, is further stressing balance sheets.
